Advertisement

Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study)

  • Masashi Fujii
Review Article

Abstract

Study rationale, objectives, design, methods, and statistical considerations of an ongoing phase III study comparing S-1 alone versus the S-1/docetaxel combination are reviewed. This study is a prospective, multicenter, multinational, nonblinded, randomized, phase III study of subjects with advanced gastric cancer. Subjects are to be randomly assigned to 3-week cycles of Treatment Arm A (docetaxel and S-1) or 6-week cycles of Treatment Arm B (S-1 only). The primary objective of the study is to compare median overall survival of the test arm (docetaxel and S-1) to the control arm (S-1 only) in subjects with advanced or recurrent gastric cancer. The secondary objectives of the study are to assess the time-to-tumor progression (TTP), defined as time from randomization to date of first documentation of progressive disease (PD), to determine the clinical response (RR), defined as the sum of complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST), and to evaluate the safety of the two regimens. A total of 628 subjects (314 in each treatment arm) will be enrolled. Subject enrollment began in September 2005 and lasts approximately 3 years. We have already enrolled 556 patients (88.5%: Japan, 346 cases; Korea, 210 cases) from 103 centers (Japan, 86 centers; Korea, 17 centers) between December 2005 and February 2008. We are expecting full enrollment at the end of August 2008. The JACCRO GC-03 study is now ongoing. After 2 years follow-up from full enrollment, in 2010 we will report the final results of this study.

Key words

Gastric cancer Chemotherapy Phase III study S-1 Docetaxel 

References

  1. 1.
    Tsukuma H (ed) (2002) Progress Report of the Research Group for Population-based Cancer Registration in Japan. Cancer Statistics: 2002 Shinohara Shuppan, TokyoGoogle Scholar
  2. 2.
    Kitagawa T, Tsukuma H, Ajiki K, et al. (1999) Prediction of cancer incidence in Japan. In: Tominaga S, et al. (eds) Cancer Statistics: 1999. Shinohara Shuppan, TokyoGoogle Scholar
  3. 3.
    Comis S (1974) Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rep 1:221CrossRefGoogle Scholar
  4. 4.
    Cocconi G, DeLisi V, DiBlasio B (1982) Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66:1263PubMedGoogle Scholar
  5. 5.
    The Gastrointestinal Tumor Study Group. (1979) Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1871Google Scholar
  6. 6.
    Moertel CG, Lavin PT (1979) Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1863PubMedGoogle Scholar
  7. 7.
    Preusser P, Achterrath W, Wilke H, et al. (1988) Chemotherapy of gastric cancer [Review]. Cancer Treat Rep 15:257CrossRefGoogle Scholar
  8. 8.
    Murad AM, Santiago FF, Petroianu A, et al. (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (Phila) 72:37–41CrossRefGoogle Scholar
  9. 9.
    Pyrhonen S, Kuitunen T, Nyandoto P, et al. (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591PubMedGoogle Scholar
  10. 10.
    Waters JS, Norman A, Cunningham D, et al. (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269–272PubMedCrossRefGoogle Scholar
  11. 11.
    Ohtsu A, Shimada Y, Shirao K, et al. (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59PubMedCrossRefGoogle Scholar
  12. 12.
    Sakata Y, Ohtsu A, Horikoshi N, et al. (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer subjects. Eur J Cancer 34:1715–1720PubMedCrossRefGoogle Scholar
  13. 13.
    Sulkes A, Smyth J, Sessa C, et al. (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70:380–383PubMedGoogle Scholar
  14. 14.
    Einzig AI, Neuberg D, Remick SC, et al. (1996) Phase II trial of docetaxel (Taxotere) in subjects with adenocarcinomas of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293. Med Oncol 13:87–93PubMedCrossRefGoogle Scholar
  15. 15.
    Taguchi T, Sakata Y, Kanamaru R, et al. (1998) Late phase II clinical study of RP56976 (docetaxel) in subjects with advance/recurrent gastric carcinoma: a Japanese Cooperative Study Group Trial (Group A). Jpn J Cancer Chemother 25:1915–1924Google Scholar
  16. 16.
    Roth AD, Maibach R, Falk S, et al. (2004) Docetaxel-cisplatin-5-FU (TCF) versus docetaxel-displatin (TC) versus epirubicincisplatin-5-FU (ECF) as systemic treatment for advanced gastric carcinoma (ACG): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 23:317 (abstract 4020)Google Scholar
  17. 17.
    Moiseyenko VM, Ajani JA, Tjulandin A, et al. (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23:308s (abstract 4002)Google Scholar
  18. 18.
    Yoshida K, Ninomiya M, Takakura N, et al. (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3042–3047CrossRefGoogle Scholar
  19. 19.
    Yamaguchi K, Shimamura T, Hyodo I, et al. (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803–1808PubMedCrossRefGoogle Scholar
  20. 20.
    Verweij J (1999) Rational design of new tumor-activated cytotoxic agents. Oncology. 57:9PubMedCrossRefGoogle Scholar
  21. 21.
    Kurosumi M, Tabei T, Suemasu K, et al. (2000) Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neo-adjuvant chemotherapy in advanced breast cancer subjects. Oncol Rep 7:945PubMedGoogle Scholar
  22. 22.
    Yoshida K, Nishiyama M, Toge T, et al. (2003) Combination phase I/II study of S-1 and docetaxel with advanced or recurrent gastric cancer. Proc Am Soc Clin Oncol 22:322 (abstract 1292)Google Scholar

Copyright information

© Japan Society of Clinical Oncology 2008

Authors and Affiliations

  1. 1.Devision of Digestive SurgeryNihon University School of MedicineTokyoJapan

Personalised recommendations